Abstract 879P
Background
To screen potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with a subgroup analysis based on the patients treated with immunotherapy and examine the prognostic significance of CDKN2A mutations.
Methods
This single-center retrospective study analyzed the Foundation Medicine (FM) next-generation sequencing (NGS) data from patients with recurrent or metastatic HNSCC who underwent NGS between January 1, 2019, to December 31, 2021. The patients were grouped according to CDKN2A loss-of-function (LOF) vs. wild-type (WT). A subgroup analysis was performed on the patients treated with immunotherapy.
Results
Seventy-seven patients (62 with immunotherapy) were included. The median follow-up was 22.6 months. The median OS was 16.5 months in the CDKN2A LOF group and 30.0 months in the CDKN2A WT group (P=0.014). The female sex (HR=4.526, 95%CI: 1.934-10.180, P=0.0003) and CDKN2A LOF (HR=2.311, 95%CI: 1.156-4.748, P=0.019) were independently associated with mortality in patients with recurrent or metastatic HNCSS. In patients with immunotherapy, the median OS was 19.8 months, or 11.7 months in the CDKN2A LOF group and 22.5 months in the CDKN2A WT group (P=0.017). The female sex (HR=4.022, 95%CI: 1.417-10.710, P=0.006), CDKN2A LOF (HR=4.389, 95%CI: 1.782-11.460, P=0.002), and CPS <1 (HR=17.20, 95%CI: 4.134-79.550, P<0.0001) were independently associated with mortality in patients with recurrent or metastatic HNCSS treated with immunotherapy.
Conclusions
LOF alterations in the CDKN2A gene are independently associated with poor survival in patients with HNSCC, including those treated with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ye Guo.
Funding
Beijing CSCO Clinical Oncology Research Foundation (NO.Y-XD2019-069,2019.07-2021.07).
Disclosure
Y. Guo: Financial Interests, Personal, Invited Speaker: Merck Serono, Roche, MSD, BMS, BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12